glp 1 and heartburn Support for Patients on GLP-1 Medications | Barimelts Heartburn and GLP-1 Treatments

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with adverse outcomes such as cirrhosis, malignancy, transplantation, and mortality

The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%

Explore evidence-based natural alternatives to GLP1: fermentable fiber, protein timing, targeted supplements like berberine, probiotics, exercise and Tonums oral Motus trial results

Explores the potential long-term side effects associated with GLP-1 medications and chronic constipation